Skip to main content
Northwestern University Feinberg School of Medicine
Department of Neurological Surgery

Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page, and find specific trials by searching for a disease or condition below.

For pediatric clinical trials, visit the Ann & Robert H. Lurie Children's Hospital of Chicago website.

For more information on neuro-oncology clinical trials, visit the Robert H. Lurie Comprehensive Cancer Center of Northwestern University website.

Please contact Katarzyna Pituch, Director of Clinical Research at (312) 695-1060 or katarzyna.pituch@northwestern.edu for more information on trials.

 
Trials

NRG BN012

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in …

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.

Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.

Eligibility Criteria

Some of the eligibility criteria include:

· Radiographic confirmation of 1-4 brain metastases

· Participants must be 18 or older

· Known active or history of invasive non-central nervous system (CNS) primary cancer based on documented pathologic diagnosis within the past 3 years cancer based on documented pathologic diagnosis within the past 3 years

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Principal InvestigatorMagill, Stephen T.Magill, Stephen T.
Location(s)
  • Map it 201 E. Huron St.
    Chicago, IL
  • Map it 4405 Weaver Pkwy
    Warrenville, IL
ClinicalTrials.gov IdentifierNCT05438212IRB number STU00218228
More Info
Copy Study URL to Clipboard Copy

RESET-RA

This study will evaluate the safety and effectiveness of the SetPoint Medical System (study device) for the treatment of patients with active, moderate-to-severe rheumatoid arthritis (RA), who have had an inadequate response or intolerance to biologic or targeted synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs).…

This study will evaluate the safety and effectiveness of the SetPoint Medical System (study device) for the treatment of patients with active, moderate-to-severe rheumatoid arthritis (RA), who have had an inadequate response or intolerance to biologic or targeted synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs).

Eligibility Criteria

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
Principal InvestigatorRuderman, Eric MRuderman, Eric M
Location(s)
  • Map it 259 E. Erie St. Nineteenth Floor
    Chicago, IL
  • Map it 675 N. Saint Clair St. Fourteenth Floor, Suite 100
    Chicago, IL
ClinicalTrials.gov IdentifierNCT04539964IRB number STU00213547
More Info
Keywords rheumatoid arthritis RA
Email Seagrist, John Frederick Phone (312)-503-0565
Copy Study URL to Clipboard Copy

Evoked Compound Action Potentials for Parkinson’s Disease (eCAP-PD) Study: A prospective, multicenter, single-arm feasibility study examining ECAP-controlled, closed-loop spinal cord stimulation for Parkinson’s Disease

The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.…

The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.

Eligibility Criteria

Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease.

Principal InvestigatorVerhagen Metman, LeonardVerhagen Metman, Leonard
ClinicalTrials.gov IdentifierNCT02924129IRB number STU00220312
More Info
Email Jabbarinejad, Roxana Phone
Copy Study URL to Clipboard Copy

Follow Neurological Surgery on FacebookInstagram